Clinical trials recruiting for HER2-positive Metastatic Breast Cancer
8
Recruiting trials
22
US states with sites
8
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Pertuzumab | 2 |
| Pyrotinib | 2 |
| Trastuzumab | 2 |
| ALX148 | 1 |
| BBO-10203 | 1 |
| Bevacizumab | 1 |
| Capecitabine tablets | 1 |
| Dalpiciclib | 1 |
| Disitamab vedotin | 1 |
| Endocrine Therapy 1 | 1 |
| FOLFOX | 1 |
| Fam-Trastuzumab Deruxtecan-Nxki | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 3 |
| California | 2 |
| Florida | 2 |
| Illinois | 2 |
| Indiana | 2 |
| New York | 2 |
| Washington | 2 |
| Alabama | 1 |
| Arizona | 1 |
| Colorado | 1 |
| Connecticut | 1 |
| District of Columbia | 1 |
Top cities
Houston, Texas 3Chicago, Illinois 2New Lenox, Illinois 2Orland Park, Illinois 2San Francisco, California 2Seattle, Washington 2Tampa, Florida 2Aurora, Colorado 1Baltimore, Maryland 1Birmingham, Alabama 1
Self-screener
Recruiting trials
- Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
- Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
- Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
- Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- PRE-ISPY Phase I/II Oncology Platform Program
- QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
- SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No Surveillance
Related conditions
Trials recruiting for HER2-positive Metastatic Breast Cancer often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Solid Tumor, Adult 38Metastatic breast cancer 131HER2 Mutation-Related Tumors 3HER2 Low Breast Carcinoma 5Advanced Breast Cancer 61Triple-negative breast cancer 138Solid Carcinoma 6Rectal Neoplasms 14Rectal cancer 152
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for HER2-positive Metastatic Breast Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.